Literature DB >> 1371338

Loss of c-kit expression in cultured melanoma cells.

N Lassam1, S Bickford.   

Abstract

The proto-oncogene c-kit encodes a receptor tyrosine kinase which has been shown to play a key role in melanocyte development. In this report we asked whether the c-kit gene product is also involved in promoting the growth of transformed melanocytes. We found that, while c-Kit protein was readily observed in normal human neonatal and adult melanocytes, the majority of cell lines established from human melanoma samples did not express detectable levels of c-kit mRNA or protein. A similar pattern of differential expression was also observed in normal and transformed murine melanocytes. Our findings raise the possibility that a marked reduction in c-kit gene expression either promotes or is a consequence of transformation in melanocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371338

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

2.  Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population.

Authors:  Syed Rizwan Hussain; Sunil G Babu; Syed Tasleem Raza; Pradyumn Singh; Faisal Ahmed; Hena Naqvi; Farzana Mahdi
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

Review 3.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

Authors:  F Laugier; J Delyon; J André; A Bensussan; N Dumaz
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

Review 5.  Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.

Authors:  Yunyi Kong; Suresh M Kumar; Xiaowei Xu
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

6.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Spontaneous malignant transformation of melanocytes explanted from Wf/Wf mice with a Kit kinase-domain mutation.

Authors:  L Larue; N Dougherty; S Porter; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842

9.  Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

Authors:  S Huang; D Jean; M Luca; M A Tainsky; M Bar-Eli
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

10.  KIT is a frequent target for epigenetic silencing in cutaneous melanoma.

Authors:  Christina Dahl; Cecilie Abildgaard; Rikke Riber-Hansen; Torben Steiniche; Johanne Lade-Keller; Per Guldberg
Journal:  J Invest Dermatol       Date:  2014-09-01       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.